Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gallus Acquires Laureate

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
Strengthens biologics CMO business with acquisition of Laureate.

Gallus BioPharmaceuticals, LLC has announced its acquisition of Laureate Biopharmaceutical Services, Inc. (Laureate), a full service biologics CMO located in Princeton, New Jersey.

This acquisition doubles Gallus’ process development (PD) and clinical drug substance manufacturing capacity, adds full protein characterization, testing and clinical fill-finish capability and offers a seamless development pathway for clients - from early stage PD and clinical manufacturing to commercial manufacturing.

United by a common mission to deliver outstanding clinical and commercial CMO services, the merged companies combine two organizations with proven track records and offer clients two Centers of Excellence for manufacturing therapeutic proteins using mammalian cell-culture: The Princeton site is a Center of Excellence for PD solutions and manufacture of clinical-stage products, including fill-finish; the St. Louis site is a Center of Excellence for PD, clinical and commercial manufacture of biopharmaceutical products.

Both sites are FDA approved, while the St. Louis site is also licensed by every major regulatory authority globally.

Gallus, a pure-play CMO, now has multiple clinical and commercial suites at the two sites, with 50L to 2,000L GMP single-use platforms from Xcellerex™ and HyClone™ in addition to 50L to 2,000L fixed and flexible stainless steel bioreactors and associated downstream purification for drug substance.

Additionally, clinical fill-finish capabilities are part of the Princeton site. All of these services will be delivered by the combined team of 350 experienced and dedicated staff.

Michael A. Griffith, Laureate CEO, who will support the transition for several months, stated that, "The merger of Laureate into Gallus benefits our clients and our employees by creating a more secure and diverse platform including important additional technologies and capabilities. Our client portfolio includes late-stage clinical programs advancing towards launch that will immediately benefit from the commercial readiness of the Gallus St. Louis site. Importantly, we believe that the service mindsets of Gallus and Laureate are well matched."

Mark R. Bamforth, Gallus President and CEO, stated “This acquisition is another important step towards realizing Gallus’ vision to be the most trusted provider of world class biologics manufacturing and development services for the pharmaceutical and biotechnology industry. By combining Laureate and Gallus, we double the development and clinical capacity of Gallus with a uniquely flexible combination of stainless steel and single use technologies and capacities to suit every client’s process needs. Critically, we have an established, reliable commercial pathway for late stage molecules and expect to continue to grow our organization and make further capital investments to serve client needs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gallus and GE Healthcare Win Global Bioprocessing Industry Award
Advanced single-use biomanufacturing facility designed and built in just nine months.
Thursday, October 30, 2014
Gallus Enters Clinical cGMP Manufacturing Agreement with Symphogen
Agreement to manufacture Symphogen’s antibody mixture product candidates.
Saturday, March 01, 2014
Gallus Announces Completion of $5 Million Process Development Expansion
Expansion provides laboratory space and instrumentation to support Gallus’ growth.
Friday, February 07, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!